The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...
The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the ...
To Pay Chinese player up to $131.6 million for subcutaneous & intravenous formulations of HLX15 “The agreement combines Dr Reddy’s global commercial presence with Henlius’ proven ...
Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...
Singhi shared his insights into the primary advantages of utilizing the subcutaneous formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) compared with the intravenous (IV) version in ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback